{"id":"https://openalex.org/W2003444892","doi":"https://doi.org/10.1177/0091270006291622","title":"Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men","display_name":"Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men","alternate_titles":[],"publication_year":2006,"publication_date":"2006-09-20","ids":{"openalex":"https://openalex.org/W2003444892","doi":"https://doi.org/10.1177/0091270006291622","mag":"2003444892","pmid":"https://pubmed.ncbi.nlm.nih.gov/16988207"},"language":"en","primary_location":{"id":"doi:10.1177/0091270006291622","doi":"https://doi.org/10.1177/0091270006291622","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270006291622","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2003444892"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112090783","display_name":"Danny Soon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165932596","display_name":"National University of Singapore","ror":"https://ror.org/01tgyzw49","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596"]}],"countries":["SG"],"is_corresponding":true,"raw_author_name":"Danny Soon","raw_affiliation_strings":["Lilly-NUS Centre for Clinical Pharmacology, Level 6, Clinical Research Centre, MD 11, National University of Singapore, 10 Medical Drive, Singapore 117597, Singapore. soon_danny@lilly.com","Lilly\u2010NUS Centre for Clinical Pharmacology, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly-NUS Centre for Clinical Pharmacology, Level 6, Clinical Research Centre, MD 11, National University of Singapore, 10 Medical Drive, Singapore 117597, Singapore. soon_danny@lilly.com","institution_ids":["https://openalex.org/I165932596"]},{"raw_affiliation_string":"Lilly\u2010NUS Centre for Clinical Pharmacology, Singapore","institution_ids":["https://openalex.org/I165932596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079794570","display_name":"Prajakti A. Kothare","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prajakti A. Kothare","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064098013","display_name":"Helle Linnebjerg","orcid":"https://orcid.org/0000-0001-5849-921X","observed_orcids":["https://orcid.org/0000-0001-5849-921X"]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Helle Linnebjerg","raw_affiliation_strings":["Eli Lilly and Company, Windlesham, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Windlesham, United Kingdom","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100716431","display_name":"Soomin Park","orcid":"https://orcid.org/0000-0001-7144-8361","observed_orcids":["https://orcid.org/0000-0001-7144-8361"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Soomin Park","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069003135","display_name":"Eunice Yuen","orcid":"https://orcid.org/0000-0003-2145-6368","observed_orcids":["https://orcid.org/0000-0003-2145-6368"]},"institutions":[{"id":"https://openalex.org/I165932596","display_name":"National University of Singapore","ror":"https://ror.org/01tgyzw49","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Eunice Yuen","raw_affiliation_strings":["Lilly-NUS Centre for Clinical Pharmacology, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly-NUS Centre for Clinical Pharmacology, Singapore","institution_ids":["https://openalex.org/I165932596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058443646","display_name":"Kenneth F. Mace","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth F. Mace","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113704708","display_name":"Stephen D. Wise","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165932596","display_name":"National University of Singapore","ror":"https://ror.org/01tgyzw49","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Stephen D. Wise","raw_affiliation_strings":["Lilly-NUS Centre for Clinical Pharmacology, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly-NUS Centre for Clinical Pharmacology, Singapore","institution_ids":["https://openalex.org/I165932596"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5112090783"],"corresponding_institution_ids":["https://openalex.org/I165932596"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":3.4252,"has_fulltext":false,"cited_by_count":54,"citation_normalized_percentile":{"value":0.92170543,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"46","issue":"10","first_page":"1179","last_page":"1187"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":1.0},{"id":"https://openalex.org/keywords/warfarin","display_name":"warfarin","score":1.0},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9229999780654907},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9599999785423279},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.996999979019165},{"id":"https://openalex.org/keywords/gastric-emptying","display_name":"gastric emptying","score":0.8560000061988831},{"id":"https://openalex.org/keywords/oral-drug-absorption","display_name":"oral drug absorption","score":0.6650000214576721},{"id":"https://openalex.org/keywords/anticoagulant-activity","display_name":"anticoagulant activity","score":0.8820000290870667},{"id":"https://openalex.org/keywords/international-normalized-ratio","display_name":"international normalized ratio","score":0.7799999713897705},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8199999928474426},{"id":"https://openalex.org/keywords/narrow-therapeutic-index-drugs","display_name":"narrow therapeutic index drugs","score":0.7770000100135803}],"concepts":[{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.9386301040649414},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.841028094291687},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.823907732963562},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.7644134759902954},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7603786587715149},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6631090641021729},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5676777362823486},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5077186822891235},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.4552648365497589},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3395424783229828},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.33889520168304443},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.2211475968360901},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.22066226601600647},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.14418530464172363},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.1323501467704773}],"mesh":[{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001189","descriptor_name":"Aryl Hydrocarbon Hydroxylases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002853","descriptor_name":"Chromatography, Liquid","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006239","descriptor_name":"Haplotypes","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D006261","descriptor_name":"Headache","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013058","descriptor_name":"Mass Spectrometry","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014859","descriptor_name":"Warfarin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014859","descriptor_name":"Warfarin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014859","descriptor_name":"Warfarin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019934","descriptor_name":"International Normalized Ratio","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D044466","descriptor_name":"Asian People","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D065729","descriptor_name":"Cytochrome P-450 CYP2C9","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/0091270006291622","doi":"https://doi.org/10.1177/0091270006291622","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270006291622","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:16988207","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16988207","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1502407336","https://openalex.org/W1965277351","https://openalex.org/W1973774410","https://openalex.org/W1976367840","https://openalex.org/W1984740259","https://openalex.org/W1986085856","https://openalex.org/W1987345639","https://openalex.org/W1998663385","https://openalex.org/W2001592873","https://openalex.org/W2011258029","https://openalex.org/W2021781593","https://openalex.org/W2084868493","https://openalex.org/W2096698984","https://openalex.org/W2101613382","https://openalex.org/W2102230312","https://openalex.org/W2105238556","https://openalex.org/W2112940339","https://openalex.org/W2135757495","https://openalex.org/W2136254957","https://openalex.org/W2150738344","https://openalex.org/W2162934281","https://openalex.org/W2163536623","https://openalex.org/W2167984392","https://openalex.org/W2315470501","https://openalex.org/W2344620176","https://openalex.org/W2506210560","https://openalex.org/W2791114118","https://openalex.org/W4239393784"],"related_works":["https://openalex.org/W2320827728","https://openalex.org/W4404821383","https://openalex.org/W3011481206","https://openalex.org/W2047243236","https://openalex.org/W2001592873","https://openalex.org/W2020787870","https://openalex.org/W1586975016","https://openalex.org/W2149415752","https://openalex.org/W1991728240","https://openalex.org/W4405053087"],"abstract_inverted_index":{"Exenatide,":[0],"a":[1,43,62,150],"treatment":[2],"for":[3,108],"type":[4],"2":[5],"diabetes,":[6],"slows":[7],"gastric":[8],"emptying":[9],"as":[10],"part":[11],"of":[12,21,33,41,59,105,123,144],"its":[13],"pharmacologic":[14],"action":[15],"and":[16,39,71,136,142],"may":[17],"alter":[18],"the":[19,31,37,103,109,112,121,124,140],"absorption":[20],"concomitant":[22],"oral":[23,57],"drugs.":[24],"This":[25],"open-label,":[26],"2-period,":[27],"fixed-sequence":[28],"study":[29],"evaluated":[30],"influence":[32],"exenatide":[34,76],"coadministration":[35],"on":[36],"pharmacokinetics":[38],"pharmacodynamics":[40],"warfarin,":[42,60],"narrow":[44],"therapeutic":[45],"index":[46],"drug,":[47],"in":[48,68,80,89,99],"healthy":[49],"men":[50],"(N":[51],"=":[52],"16).":[53],"A":[54],"single,":[55],"25-mg":[56],"dose":[58],"with":[61,73],"standardized":[63],"breakfast,":[64],"was":[65],"administered":[66],"alone":[67],"period":[69,81],"1":[70],"concomitantly":[72],"10":[74],"microg":[75],"subcutaneous":[77],"twice":[78],"daily":[79],"2.":[82],"Exenatide":[83],"did":[84],"not":[85,148],"produce":[86],"significant":[87],"changes":[88,146],"R-":[90],"or":[91,129],"S-warfarin":[92],"pharmacokinetics.":[93],"Although":[94],"there":[95],"were":[96],"minor":[97],"reductions":[98],"warfarin":[100],"anticoagulant":[101],"effect,":[102],"ratios":[104],"geometric":[106],"means":[107],"area":[110],"under":[111],"international":[113],"normalized":[114],"ratio":[115],"(INR)-time":[116],"curve":[117],"from":[118,153],"dosing":[119],"until":[120],"time":[122],"last":[125],"measurable":[126],"INR":[127,131],"value":[128],"maximum-observed":[130],"response":[132],"being":[133],"0.94":[134],"(0.93-0.96)":[135],"0.88":[137],"(0.84-0.92),":[138],"respectively,":[139],"magnitude":[141],"direction":[143],"these":[145],"do":[147],"suggest":[149],"safety":[151],"concern":[152],"this":[154],"interaction.":[155]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2003444892","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
